BioSniper

Phase 2 Readouts

Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.

0 upcoming events tracked. Updated hourly.

No upcoming phase 2 readouts currently scheduled. Check back soon.

Learn more

Biotech Clinical Trial Phases Explained: What Investors Need to Know

A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.

Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know

Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.

FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors

Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.

Browse by event type

PDUFA DatesAdCom MeetingsPhase 3 ReadoutsFDA ApprovalsEarningsAll Events
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle